Aberrations in this pathway are described in many cancers, including cervical cancer, and this has led to the development of PI3K-inhibitors and Akt-inhibitors as potential cancer therapies, with some already having reached clinical trials.[31–34] Mammalian target of rapamycin (mTOR) is a key protein downstream the PI3K-Akt pathway and mTOR-targeting agents (everolimus, temsirolimus) are currently used for several cancers in clinical practice.[35–38] The role that PI3K-Akt pathway targeting can play in cervical cancer therapy remains to be investigated further.[39]. The gene discussed is PIK3CA; the disease is cervical cancer.